Thus, targeting TNFR2 by this approach offers a promising and novel treatment of cancer paradigm for patients.Methods:Safety and tolerability profile of BI-1808 as a single agent and in combination with pembrolizumab is currently being investigated in the Phase 1/2a clinical trial 19-BI-1808-01...
The poster presentation, entitled "Phase 1/2a Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2) as Single Agent and in Combination with Pembrolizumab"include data from the BI-1808 monotherapy arm of the Phase 1 study and...
“We are pleased that our Phase 1/2a trial of BI-1808 is progressing as planned. These interim results are a further reinforcement of the very promising data generated so far on BI-1808, with a very favorable tolerability profile and no safety conc...
Nishiwaki Y, Kudoh S, Yokota S, Matsui K, Semba H, Nakagawa K, Takada Y, Ando M, Shibata T, Saijo N (2009) Phase III trial of docetaxel plus gemcitabine versus docetaxel in second- line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG...
Diabetic cardiomyo- pathy: a clinical entity or a cluster of molecular heart changes? Eur J Clin Invest. 2016;46:947–53. 9. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovas- cular disorders in diabetes. Circ Res. 2016;118:1808–29. 10. Russo I, Frangogiannis NG. ...
Cytokine and stem cell-based therapies aimed at micro-revascularization and myocardial repair have been the subject of extensive research, demonstrating encouraging experimental promise. However, subsequent investigation in prospective randomized clinical trials yielded results that were statistically significant ...
BioInvent’s lead compound BI-1206, evaluated in two separate Phase I trials for hematological or solid tumors, is one of three ongoing drug candidates in clinical development. The company initiated a Phase I/IIa trial of anti-TNFR2 antibody BI-1808 in...